LMU is the leading teaching and research university in Germany, ranking 1st in Germany in the latest Times Higher Education World University Ranking. LMU Klinikum – KUM acts in ARTILLERY as affiliated entity of LMU. This setup is required to ensure compliance with Bavarian legislation. In the EU Framework Programme Horizon 2020, LMU participated in more than 280 projects, thereof in 10 as coordinating institution, which makes this organization highly experience in EU projects. Also, KUM leading researcher has been PI of a successful decision impact trial (WGS-PRIMe study) in breast cancer patients, making her well suited to lead ARTILLERY WP4. The volume of breast cancer patients treated each year within the
department of radiotherapy is also substantial (number of patients per year) 350 patients.
Friederike Banning, MD, PhD
Friederike Banning, MD, PhD is a physician at the Breast Cancer, Study Site at the Department of Obstetrics and Gynecology, Ludwig- Maximilians University, Munich. She completed her medical degree at the Universities of Bonn and Bochum, Germany in 1995. Within the same year, she completed her medical doctoral thesis in the area of Experimental
Endocrinology. Additionally,
Friederike Banning received further training in Pain Therapy at Klinikum Rechts der Isar and Ludwig-Maximilians University Munich as well as a Certificate of Nutrition at the German Academy for Nutritional Medicine. Friederike Banning gained a broad working experience from working in the department of Anesthesiology at the Ludwig-Maximilians University, Munich, as study physician at Harrison
Clinical Research Germany GmbH in Munich, and the Diabetes Centre at Ludwig Maximilians University, Munich. Therefore, she has carried out from year 2002 until now numerous national and international Phase I- IV trials for different medical indications.
She also has experience in trial conduction in the position of a principal, a responsible
investigator as well as a sub investigator. Her special interests lie in Breast Cancer and Diabetology Research. Friederike Banning also broadened her experience as an active researcher by publishing papers concerning Diabetology and Covid-19.
As physician at the Breast Cancer, Study Site of Ludwig-Maximilians University, Munich Friederike Banning conducts various Breast Cancer Studies for early as well as metastatic breast cancer particularly with novel targeted compounds and individualized treatment strategies.
Professor Nadia Harbeck, MD, PhD
Nadia Harbeck, MD, PhD, is Director of the Breast Center, the Center for Hereditary Breast and Ovarian Cancer, and holds the chair for Conservative Oncology at the Dept. of OB&GYN, LMU University Hospital, Munich, Germany. She obtained her specialist degree (OB&GYN) at the Technical University of Munich (TUM) and her medical degree from the Ludwig-Maximilians-University of Munich (LMU).
Professor Harbeck is the current chair of the ESMO (European Society for Medical Oncology) Early Breast Cancer Faculty; she served as ESMO Director of Education and member of the ESMO Executive Board (2023-2025) as well as Subject Editor of the ESMO Breast Cancer Guidelines (2022-2025). She was member of the ASCO Annual Meeting Educational Committee (2022-2025). She is member of the expert panel issuing the German AGO recommendations for breast cancer therapy (www.ago-online.de). She is co-director of the WSG (Women’s Cancer Study Group) (www.wsg-online.com). From 2009-2015, she served on the EORTC Executive Board as chair of the Translational Research Division. Professor Harbeck is principal investigator or steering committee member of numerous breast cancer trials, particularly with novel targeted compounds and individualized treatment strategies. She has a strong interest in eHealth and is co-developer of CANKADO, an international digital patient diary (www.cankado.com).
Professor Harbeck is one of the most frequently cited clinical researchers worldwide (Highly Cited Researcher 2021-2024). She has authored more than 830 papers in peer-reviewed journals (h-index 103) and is coordinating editor-in-chief of Breast Care (Karger Publishers). She co-directed the annual ESMO AACR EORTC Methods in Clinical Cancer Research Workshop (MCCR) from 20218-2019 and 2022-2024 and is a panel member of several international breast cancer consensus conferences.
In 2025, Prof. Harbeck received the Bavarian Order of Merit from the Governor of Bavaria, Germany. She is Adjunct Professor of the University of Vienna, Austria, and recipient of the 2023 German Cancer Award and the 2020 ESMO Lifetime Achievement Award. She received several additional recognitions of her clinical and translational research such as the 2021 UPO Award for Women in Academy and Research, the 2015 Bavarian Cancer Patient Award, the 2012 Claudia von Schilling Award, the 2008 EBCC Award, the 2002 AGO Schmidt-Matthiesen Award, a 2001 AACR Award, and the 2001 ASCO Fellowship Merit Award for the highest ranking abstract.